Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city-Reference-Cited by-同舟云学术

Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city

Published:2019-09 Issue: Volume:34 Page:77-82
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Ashtari Fereshteh,Mehdipour Roshanak,Shaygannejad Vahid,Mansourian Marjan

Funder

Isfahan University of Medical Sciences

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference36 articles.

1. Treatment of NMO relapse in the elderly: Rituximab when plasma exchange fails?;Bourre;Acta Neurol. Belg.,2013

2. An overview of the current clinical use of the anti-CD20 monoclonal antibody Rituximab;Boye;Ann. Oncol.,2003

3. An update on the evidence for the efficacy and safety of Rituximab in the management of neuromyelitis optica;Collongues;Ther. Adv. Neurol. Disord.,2016

4. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica;Costanzi;Neurology,2011

5. Changes in B and T cell subsets and NMO-IgG/AQP-4 levels after immunoglobulins and Rituximab treatment for an acute attack of neuromyelitis optica;de Andrésa;Neurología,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidemiologic and clinical characteristics of neuromyelitis optica spectrum disorder patients, A seven years follow-up study from Iran;Multiple Sclerosis and Related Disorders;2023-09

2. Systematic Review of Treatment Options and Therapeutic Responses for Lesions of the Sella and Orbit: Evidence-Based Recommendations;World Neurosurgery;2023-05

3. Different doses of Rituximab for the therapy of Neuromyelitis optica spectrum disorder: A systematic review and meta-analysis;Multiple Sclerosis and Related Disorders;2022-12

4. The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real‐world study from Turkey;International Journal of Clinical Practice;2021-04-08

5. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders;Multiple Sclerosis and Related Disorders;2021-02